Lately a new player has penetrated the market to challenge the world famous brand Botox, an Allergan product. Botox has mostly dominated the aesthetic procedures market in the US, with few real competitors. Till now the primary substitute to Botox in the US has been Dysport, though many doctors have avoided utilizing this medicine for in-office aesthetics thanks to some evidence showing that the drug tends to exhibit more local spread.

Merz, a German pharma company, is the maker of Xeomin, a botulinum toxin medication. Xeomin has been widely used in England and enjoyed by doctors and consumers alike. Last year in July, Merz released an announcement that the FDA had authorized Xeomin for aesthetic procedures in the States and that the product would be commercially available in the spring of 2012. This news is great news for aesthetics in the US!

While in the USA Xeomin is a comparatively unknown brand it has many edges over the more famous injectable Botox. Botox must be either stored in a freezer or refrigerator before reconstitution and is highly sensitive to changes in temperature as well as to agitation. As an example, when adding diluent to Botox prior to use, doctors must take great care to insert the water for injection slowly, since forceful insertion could ruin the toxin and cause it to be ineffective.

Xeomin,as opposed to Botox, is a significantly more robust substance. A significant edge over Botox is that Xeomin can be kept at room temperature and so does not necessitate special storage techniques. In addition Xeomin is much less sensitive to agitation. This means that on the part of the aesthetic practice less botulinum toxin will be harmed due to poor storage.

In contrast to the other alternative to Botox, Dysport, Xeomin is much more like Botox regarding its pharmacological profile. Xeomin injections usually remain extremely localised, meaning potentially less complications associated with local spread. Additionally a major advantage is that the units used are the same as the units used by Botox, versus Dysport where the units are not identical and can often be a little confusing for doctors.

Also, if the United States marketplace follows the European Union, the arrival of Xeomin will lead to competition which will mean cheaper prices for consumers. At the moment the cost of Botox in the US has a tendency to be around $9-12 per unit, while the price in England has a tendency to be cheaper at $7-8 per unit.

Therefore the impending penetration of Xeomin into the States will be a blessing for both clients as well as doctors.

Botox Course runs the premier injection course for medical practitioners to educate them how to inject Botox and set up succesful aesthetic medical practices. In addition to the Injection Course, medical practitioners can learn skin filler injection techniques and peeling techniques.